Author Correction: Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors

Peitao Zhang^#^{1

2}, Haixia Guan^#^{3

4}, Shukai Yuan^#¹, Huili Cheng¹, Jian Zheng⁵, Zhenlei Zhang¹, Yifan Liu¹, Yang Yu⁶, Zhaowei Meng², Xiangqian Zheng⁶, Li Zhao⁷

Affiliations

¹ The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
² Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China.
³ Department of Endocrinology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China.
⁴ The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong Province, China.
⁵ Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
⁶ Department of Thyroid and Neck Oncology, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
⁷ The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. shzhaoli@tmu.edu.cn.

^# Contributed equally.

Published Erratum

Peitao Zhang et al. Nat Commun. 2022.

. 2022 Nov 17;13(1):7025.

doi: 10.1038/s41467-022-34545-6.

Peitao Zhang^#^{1

2}, Haixia Guan^#^{3

4}, Shukai Yuan^#¹, Huili Cheng¹, Jian Zheng⁵, Zhenlei Zhang¹, Yifan Liu¹, Yang Yu⁶, Zhaowei Meng², Xiangqian Zheng⁶, Li Zhao⁷

¹ The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
² Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China.
³ Department of Endocrinology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China.
⁴ The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong Province, China.
⁵ Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
⁶ Department of Thyroid and Neck Oncology, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
⁷ The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. shzhaoli@tmu.edu.cn.

^# Contributed equally.

No abstract available

Erratum for

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.
Zhang P, Guan H, Yuan S, Cheng H, Zheng J, Zhang Z, Liu Y, Yu Y, Meng Z, Zheng X, Zhao L. Zhang P, et al. Nat Commun. 2022 Mar 24;13(1):1588. doi: 10.1038/s41467-022-29000-5. Nat Commun. 2022. PMID: 35332119 Free PMC article.